Article

Integrating population-level and cell-based signatures for drug repositioning

2023-10-26

Abstract excerpt

Drug repositioning presents a streamlined and cost-efficient way to expand the range of therapeutic possibilities. Drugs with human genetic evidence are more likely to advance successfully through clinical trials towards FDA approval. Single gene-based drug repositioning methods have been implemented, but approaches leveraging a broad spectrum of molecular signatures remain underexplored. We propose a framework ca...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 61540381-e082-5998-ae4f-6a1a9f0deceb
DOI: 10.1101/2023.10.25.564079

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Integrating population-level and cell-based signatures for drug repositioningDOI 10.1101/2023.10.25.564079Read

A genetically based computational drug repurposing framework for rapid identification of candidate compounds: application to COVID-19Semantic proximity Read

A Genetics-guided Integrative Framework for Drug Repurposing: Identifying Anti-hypertensive Drug Telmisartan for Type 2 DiabetesSemantic proximity Read

Clinical Trial and Ontology-Derived Positive and Negative Benchmark Datasets for Drug Repurposing Across Rare DiseasesSemantic proximity Read

Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and molecular data.Semantic proximity Read

RANKOR: Direct Drug Prioritization from Bulk and Single-Cell Transcriptomic SignaturesSemantic proximity Read

Integrating single-cell and bulk transcriptomic perturbation resources reveals complementary therapeutic spaces for drug repurposingSemantic proximity Read

Network reinforcement driven drug repurposing for COVID-19 by exploiting disease-gene-drug associationsSemantic proximity Read

An Agentic Platform for Drug Repurposing Unified across Molecular, Phenotypic, and Clinical ScalesSemantic proximity Read

Drug target gene-based analyses of drug repositionability in rare and intractable diseases.Semantic proximity Read

Drug Target Set Enrichment Analysis (DTSEA): A Network-Based Approach for Drug Repurposing to COVID-19Semantic proximity Read

Cell-Level Virtual ScreeningSemantic proximity Read

DR3E-Net: Drug Repurposing Network Framework Based on Deep Embedding, Differentially Expressed Genes, and Drug Side EffectsSemantic proximity Read